WHO Programme-Global Monitoring

Pharmacovigilance: Second Edition

Volumn , Issue , 2007, Pages 149-166

  Edwards, I Ralph ^a   Biriell, Cecilia ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

Bayesian Confidence Propagation Neural Network (BCPNN) knowledge detection technique; UMC in benefit harm analysis of drug safety; WHO Programme adverse reaction terminology (WHOART) and reported drugs (WHO DD) index; WHO Programme global database for ADRs; World Health Organisation (WHO) and Uppsala Monitoring Centre (UMC)

Indexed keywords

EID: 84877761701     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059210.ch12     Document Type: Chapter

References (45)

1. Bate A (2000) '"Validating" automated signal detection methods used in spontaneous reporting systems'. 16th International Conference on Pharmacoepidemiology, Barcelona.
2. Bate A (2003) The use of a Bayesian Confidence Propagation Neural Network in Pharmacovigilance. Umeå: Umeå University.
3. Bate A, Lindquist M, Edwards IR et al. (1998a) 'A Bayesian neural network method for adverse drug reaction signal generation'. European Journal of Clinical Pharmacology 54: 315-21.
4. Bate A, Lindquist M, Edwards IR et al. (1998b) 'Identifying and quantifying signals automatically'. Pharmacoepidemiology and Drug Safety 7 (Suppl. 2): 99.
5. Bate A, Lindquist M, Orre R et al. (2000) 'Automated classification of signals as group effects or drug specific on the WHO database'. 8th Annual Meeting European Society of Pharmacovigilance. Verona: Elsevier.
6. Bowdler J (1997) Effective Communications in Pharmacovigilance, Vol. 1, 1st edn. Birmingham, England: W. Lake Ltd.
7. CIOMS (1995) Harmonization of Data Fields for Electronic Transmission of Case-Report Information Internationally. Geneva: CIOMS.
8. Edwards IR (1997) 'Pharmacological basis for adverse drug reactions'. In: Speight T and Holford N, eds. Avery's Drug Treatment. Auckland: Adis International Ltd, pp. 261-99.
9. Edwards IR (1999) 'Spontaneous reporting of what? Clinical concerns about drugs'. British Journal of Clinical Pharmacology 48: 138-41.
10. Edwards IR (2000) 'The accelerating need for pharmacovigilance'. Journal of Royal College of Physicians of London 34(1): 48-51.
11. Edwards IR (2005a) 'What are the real lessons from Vioxx?' Drug Safety 28(8): 651-8.
12. Edwards IR (2005b) 'The WHO World Alliance for Patient Safety: a new challenge or an old one neglected?' Drug Safety 28(5): 379-86.
13. Edwards IR, Biriell C (1994) 'Harmonisation in pharmacovigilance'. Drug Safety 10: 93-102.
14. Edwards IR, Fucik H (1996) 'Impact and credibility of the WHO adverse reaction signals'. Drug Information Journal 30(2): 461-4.
15. Edwards IR, Hugman B (1997) 'The challenge of effectively communicating risk-benefit information'. Drug Safety 17(4): 216-27.
16. Edwards IR, Wiholm B-E, Martinez C (1996) 'Concepts in risk-benefit assessment'. Drug Safety 15(1): 1-7.
17. Edwards IR, Lindquist M, Wiholm BE, Napke E (1990) 'Quality criteria for early signals of possible adverse drug reactions'. Lancet 336: 156-8.
18. Edwards IR, Lindquist M (2000) 'Understanding andcommunication of key concepts in therapeutics'. In: Moments of Truth-Communicating Drug Safety. Verona: Elsevier.
19. Farah MH (1998) 'Consumer protection and herbal remedies'. WHO Drug Information 12(3): 141.
20. Farah MH (2000a) 'Key issues in herbal pharmacovigilance'. Adverse Drug Reactions J 2(2): 105-9.
21. Farah MH, Leon C, Edwards IR et al. (2000b) 'International monitoring of adverse health effects associated with herbal medicines'. Pharmacoepidemiology and Drug Safety 9: 105-12.
22. Lazarou J, Pomeranz BH, Corey PN (1998) 'Incidence of adverse drug reactions in hospitalized patients: a metaanalysis of prospective studies'. Journal of American Medical Association 279(15): 1200-5.
23. Lindquist M, Edwards IR (1993) 'Adverse drug reaction reporting in Europe: some problems of comparison'. International Journal of Risk and Safety in Medicine 4: 35-46.
24. Lindquist M, Edwards IR (1997) 'Risks of non-sedating antihistamines'. Lancet 349: 1322.
25. Lindquist M (1990) 'Uses and limitations of a global reporting pool'. Meeting on Methods for the Detection and Study of Unwanted Drug Effect, Kiel, Germany, 26-29 November.
26. Lindquist M (1998) 'The WHO Programme for International Drug Monitoring: the present and future'. In: Mitchard M, ed. Electronic Communication Technologies, pp. 527-49.
27. Lindquist M (2000) 'Signal detection using the WHO international database'. 8th Annual Meeting European Society of Pharmacovigilance. Verona: Elsevier.
28. Lindquist M (2003) Seeing and Observing in International Pharmacovigilance-Achievements and Prospects in Worldwide Drug Safety. Nijmegen: University of Nijmegen.
29. Lindquist M, Farah MH, Edwards R (2000) 'Monitoring of herbal medicines'. In: Clinical Pharmacology and Therapeutics. Florence: Blackwell.
30. Lindquist M, Sanderson J, Claesson C et al. (1994) 'Pharmacovigilance information on an old drug-an international study of spontaneous reports on Digoxin'. Drug Investigation 8: 73-80.
31. Lindquist M, Pettersson M, Edwards IR et al. (1996) 'Omeprazole and visual disorders: seeing alternatives'. Pharmacoepidemiology and Drug Safety 5: 27-32.
32. Lindquist M, Pettersson M, Edwards IR et al. (1997) 'How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data'. Pharmacol Toxicol 80: 211-17.
33. Lindquist M, Edwards IR, Bate A et al. (1999) 'From association to alert-a revised approach to international signal analysis'. Pharmacoepidemiology and Drug Safety 8: S15-25.
34. Meyboom RHB (2000) 'The case for good pharmacovigilance practice'. Pharmacoepidemiology and Drug Safety 9: 335-6.
35. Meyboom RHB, Lindquist M, Flygare AK et al. (2000a) 'Should therapeutic ineffectiveness be reported as an adverse drug reaction?' 8th Annual Meeting European Society of Pharmacovigilance. Verona: Elsevier.
36. Meyboom RHB, Lindquist M, Flygare A-K et al. (2000b) 'The value of reporting therapeutic ineffectiveness as an adverse drug reaction'. Drug Safety 23(2): 95-9.
37. Mills A, Edwards IR (1999) 'Venous thromboembolism and the pill'. Human Reproduction 14(1): 7-10.
38. Norén GN, Orre R, Bate A (2005) 'A hit-miss model for duplicate detection in the WHO drug safety database'. Proceedings of the Eleventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, Chicago, IL.
39. Orre R, Lanser A, Bate A et al. (2000) 'Bayesian neural networks with confidence estimations applied to data mining'. Computational Statistics and Data Analysis 34(8): 473-93.
40. Pirmohamed M, James S, Meakin S et al. (2004) 'Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients'. British Medical Journal 329(7456): 15-19.
41. Ståhl M, Edwards I, Bowring G et al. (2003) 'Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of National Pharmacovigilance Centres'. Drug Safety 26(10): 721-7.
42. Ståhl M, Lindquist M, Edwards IR, Brown EG (2004) 'Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database'. Pharmacoepidemiology and Drug Safety 13(6): 355-63.
43. Uppsala Monitoring Centre (1998) Effective Communications in Pharmacovigilance-The Erice Report. Uppsala: Uppsala Monitoring Centre.
44. WHO and Uppsala Monitoring Centre (2000) Safety Monitoring of Medicinal Products. Uppsala: WHO and Uppsala Monitoring Centre.
45. WHO and Uppsala Monitoring Centre (2002) The Importance of Pharmacovigilance. Geneva: WHO and Uppsala Monitoring Centre.